Home  |  Contact

Cellosaurus Raji (CVCL_0511)

[Text version]

Cell line name Raji
Synonyms RAJI; P1-Raji; GM04671
Accession CVCL_0511
Resource Identification Initiative To cite this cell line use: Raji (RRID:CVCL_0511)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: ENCODE project common cell types; tier 3.
Part of: LL-100 blood cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Characteristics: Contains 50-60 integrated copies of the EBV genome. One copy is integrated in intron 1 of the BACH2 gene.
Characteristics: Genetic heterogeneous, consists of 2 subclones (PubMed=27566572).
Doubling time: 23.2 hours (PubMed=8847894); ~24-36 hours (DSMZ); ~20 hours (NIH-ARP).
Microsatellite instability: Stable (MSS) (Sanger).
Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: H3K27ac ChIP-seq epigenome analysis.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Omics: Virome analysis using RNAseq.
Misspelling: BAJI; In Cosmic 998718.
Sequence variations MYC-IGH gene fusion (PubMed=6306472; PubMed=6419122).
Heterozygous for TP53 p.Arg213Gln (c.638G>A) and p.Tyr234His (c.700T>C) (PubMed=8344493; CCLE; Cosmic-CLP).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*03:01,03:01
HLA-BB*15:10,15:10
HLA-CC*04:01,03:04
Class II
HLA-DQDQA1*05:01,01:01
DQB1*05:01,02:01
HLA-DRDRB1*10:01,03:01

Source: IPD-IMGT/HLA; 11295
Class I
HLA-AA*03:01:01:01
HLA-BB*15:10,15:CXU
HLA-CC*03:04:02,04:01:01:01
Class II
HLA-DPDPB1*01:01:01
HLA-DQDQA1*01:01:01,05:01:01:01
DQB1*02:01:01,05:01:01
HLA-DRDRA*01:01:01:01
DRB1*03:01:01:01,10:01:01:01
DRB3*02
Genome ancestry Source: PubMed=30894373

Origin% genome
African99.39
Native American0
East Asian, North0.6
East Asian, South0
South Asian0
European, North0
European, South0
Disease Epstein-Barr virus-related Burkitt lymphoma (NCIt: C27694)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_0R19 (B-THP-1)CVCL_6216 (DITRUD-1)CVCL_3042 (NC-37)
CVCL_UJ11 (R/ADR)CVCL_UJ12 (R/VP-16)CVCL_2699 (RAJI 'A')
CVCL_Y035 (Raji 6-TGR)CVCL_2701 (RAJI TK-)CVCL_2700 (RAJI TK+)
CVCL_LK62 (Raji-GFP)CVCL_DD98 (Raji-TG)CVCL_VL72 (Raji(A44))
CVCL_KU31 (Raji/18V)CVCL_0R22 (Raji/DC-SIGN)CVCL_3414 (Rj2.2.5)
CVCL_6218 (RUD-PICAT-1)CVCL_6219 (RUDPUT-2)CVCL_8431 (TDL-4)
Sex of cell Male
Age at sampling 11Y
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CCRID; Cosmic-CLP; DSMZ; ECACC; JCRB; PubMed=11416159; PubMed=25877200; RCB; TKG

Markers:
AmelogeninX,Y
CSF1PO10,12
D2S133822
D3S135815,16
D5S81810,13
D7S82010
D8S117914,15
D13S31713
D16S5398,11
D18S5117
D19S43314,14.2
D21S1128,31
FGA19,27
Penta D3.2,9
Penta E5,13
TH016,7
TPOX8,13
vWA16,19

Run an STR similarity search on this cell line
Web pages https://en.wikipedia.org/wiki/Raji_cell
http://genome.ucsc.edu/ENCODE/protocols/cell/human/Raji_Farnham_protocol.pdf
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/r/cell-lines-detail-27.html
http://tcpaportal.org/mclp/
http://www.cellresource.cn/fdetail.aspx?id=46
http://www.cellresource.cn/fdetail.aspx?id=397
http://www.cellresource.cn/fdetail.aspx?id=614
http://www.cellresource.cn/fdetail.aspx?id=3298
Publications

PubMed=14086209; DOI=10.1016/S0140-6736(64)92345-1
Pulvertaft R.J.V., Cantab M.D.
Cytology of Burkitt's tumour (African lymphoma).
Lancet 283:238-240(1964)

PubMed=6018567
Miles C.P., O'Neill F.
Chromosome studies of 8 in vitro lines of Burkitt's lymphoma.
Cancer Res. 27:392-402(1967)

PubMed=4894370; DOI=10.1002/1097-0142(196908)24:2<211::AID-CNCR2820240202>3.0.CO;2-3
Southam C.M., Burchenal J.H., Clarkson B.D., Tanzi A., Mackey R., McComb V.
Heterotransplantability of human cell lines derived from leukemia and lymphomas into immunologically tolerant rats.
Cancer 24:211-222(1969)

PubMed=4321974
Maurer B.A., Wilbert S.M., Imamura T.
Incidence of EB virus-containing cells in primary and secondary clones of several Burkitt lymphoma cell lines.
Cancer Res. 30:2870-2875(1970)

PubMed=4325933; DOI=10.1093/jnci/46.6.1243
Pearson G.R., Henle G., Henle W.
Production of antigens associated with Epstein-Barr virus in experimentally infected lymphoblastoid cell lines.
J. Natl. Cancer Inst. 46:1243-1250(1971)

PubMed=4122458; DOI=10.1002/ijc.2910100108
Klein G., Dombos L., Gothoskar B.
Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus.
Int. J. Cancer 10:44-57(1972)

PubMed=4364259; DOI=10.1002/ijc.2910110210
Klein G., Dombos L.
Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genome.
Int. J. Cancer 11:327-337(1973)

PubMed=4736620; DOI=10.1111/j.1469-1809.1973.tb00588.x
Povey S., Gardiner S.E., Watson B., Mowbray S., Harris H., Arthur E., Steel C.M., Blenkinsop C., Evans H.J.
Genetic studies on human lymphoblastoid lines: isozyme analysis on cell lines from forty-one different individuals and on mutants produced following exposure to a chemical mutagen.
Ann. Hum. Genet. 36:247-266(1973)

PubMed=4366935
Minowada J., Nonoyama M., Moore G.E., Rauch A.M., Pagano J.S.
The presence of the Epstein-Barr viral genome in human lymphoblastoid B-cell lines and its absence in a myeloma cell line.
Cancer Res. 34:1898-1903(1974)

PubMed=170370; DOI=10.1099/0022-1317-28-2-207
Adams A., Strander H., Cantell K.
Sensitivity of the Epstein-Barr virus transformed human lymphoid cell lines to interferon.
J. Gen. Virol. 28:207-217(1975)

PubMed=216485
Higgins N.P., Strauss B.S.
Differences in the ability of human lymphoblastoid lines to exclude bromodeoxyuridine and in their sensitivity to methyl methanesulfonate and to incorporated [3H]thymidine.
Cancer Res. 39:312-320(1979)

PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x
Povey S., Jeremiah S., Arthur E., Steel M., Klein G.
Differences in genetic stability between human cell lines from patients with and without lymphoreticular malignancy.
Ann. Hum. Genet. 44:119-133(1980)

PubMed=6265077
Pizzo P.A., Chattopadhyay S.K., Magrath I.T., Del Giacco E., Sherrick D., Gray T.
Examination of Epstein-Barr virus and C-type proviral sequences in American and African lymphomas and derivative cell lines.
Cancer Res. 41:3165-3171(1981)

PubMed=6286763
Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D., Parsons R.G.
Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.
J. Immunol. 129:1336-1342(1982)

PubMed=6306472; DOI=10.1038/304135a0
Hamlyn P.H., Rabbitts T.H.
Translocation joins c-myc and immunoglobulin gamma 1 genes in a Burkitt lymphoma revealing a third exon in the c-myc oncogene.
Nature 304:135-139(1983)

PubMed=6419122; DOI=10.1038/306760a0
Rabbitts T.H., Hamlyn P.H., Baer R.
Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma.
Nature 306:760-765(1983)

PubMed=6600440; DOI=10.1007/BF02617996
Uittenbogaart C.H., Cantor Y., Fahey J.L.
Growth of human malignant lymphoid cell lines in serum-free medium.
In Vitro 19:67-72(1983)

PubMed=6500159; DOI=10.1159/000163283
Gershwin M.E., Lentz D., Owens R.B.
Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.
Exp. Cell Biol. 52:361-370(1984)

PubMed=6547209; DOI=10.1038/309592a0
Rabbitts T.H., Forster A., Hamlyn P., Baer R.
Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma.
Nature 309:592-597(1984)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3080238
Sieverts H., Alabaster O., Goldschmidts W., Magrath I.T.
Expression of surface antigens during the cell cycle in different growth phases of American and African Burkitt's lymphoma cell lines.
Cancer Res. 46:1182-1188(1986)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3034807; DOI=10.1002/ijc.2910390622
Ohno H., Fukuhara S., Takahashi R., Mihara K.-I., Sugiyama T., Doi S., Uchino H., Toyoshima K.
c-yes and bcl-2 genes located on 18q21.3 in a follicular lymphoma cell line carrying a t(14;18) chromosomal translocation.
Int. J. Cancer 39:785-788(1987)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)

PubMed=1915267
Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.
p53 is frequently mutated in Burkitt's lymphoma cell lines.
EMBO J. 10:2879-2887(1991)

CLPUB00447
Mulivor R.A., Suchy S.F.
1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.
(In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992)

CLPUB00458
Treichel R.S.
Susceptibility to LAK-mediated cytotoxicity of multidrug-resistant variants of the human RAJI cell line is not related to expression of major cellular adhesion molecules.
Ohio J. Sci. 93:14-18(1993)

PubMed=8316623; DOI=10.2307/3578190
Evans H.H., Ricanati M., Horng M.-F., Jiang Q., Mencl J., Olive P.
DNA double-strand break rejoining deficiency in TK6 and other human B-lymphoblast cell lines.
Radiat. Res. 134:307-315(1993)

PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493
Bhatia K., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R., Magrath I.T.
Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.
FASEB J. 7:951-956(1993)

PubMed=8515068
Jain V.K., Judde J.-G., Max E.E., Magrath I.T.
Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
J. Immunol. 150:5418-5428(1993)

PubMed=7849311
Stranks G., Height S.E., Mitchell P., Jadayel D., Yuille M.A., De Lord C., Clutterbuck R.D., Treleaven J.G., Powles R.L., Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D., Millar J.L., Catovsky D., Dyer M.J.S.
Deletions and rearrangement of CDKN2 in lymphoid malignancy.
Blood 85:893-901(1995)

PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x
Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G., Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.
Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.
Br. J. Haematol. 91:350-354(1995)

PubMed=8558913
Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M., Imaizumi M., Endo M., Takano N., Konno T.
Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.
Leukemia 10:102-105(1996)

PubMed=8847894
Tani A., Tatsumi E., Nakamura F., Kumagai S., Kosaka Y., Sano K., Nakamura H., Amakawa R., Ohno H.
Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines.
Leukemia 10:1592-1603(1996)

PubMed=9473234
Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.
p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.
Blood 91:1680-1687(1998)

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=9685479; DOI=10.1093/nar/26.16.3651
Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T., Roos G.
Telomere analysis by fluorescence in situ hybridization and flow cytometry.
Nucleic Acids Res. 26:3651-3656(1998)

PubMed=9737686; DOI=10.1038/sj.leu.2401112
Zhang W., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S., Takeshita K., Takeshita A., Ohno R.
The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Leukemia 12:1383-1391(1998)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)

PubMed=9973220
Gutierrez M.I., Cherney B., Hussain A., Mostowski H., Tosato G., Magrath I.T., Bhatia K.
Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis.
Cancer Res. 59:696-703(1999)

PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x
Maesako Y., Uchiyama T., Ohno H.
Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma.
Cancer Sci. 94:774-781(2003)

PubMed=14982850; DOI=10.1016/S0002-9440(10)63184-7
Takakuwa T., Luo W.-J., Ham M.F., Sakane-Ishikawa E., Wada N., Aozasa K.
Integration of Epstein-Barr virus into chromosome 6q15 of Burkitt lymphoma cell line (Raji) induces loss of BACH2 expression.
Am. J. Pathol. 164:967-974(2004)

PubMed=15028022; DOI=10.1111/j.1440-1827.2004.01612.x
Kamimura K., Hojo H., Abe M.
Characterization of expression of protein kinase C isozymes in human B-cell lymphoma: relationship between its expression and prognosis.
Pathol. Int. 54:224-230(2004)

PubMed=15457187; DOI=10.1038/sj.leu.2403534
Karpova M.B., Schoumans J., Ernberg I., Henter J.-I., Nordenskjold M., Fadeel B.
Raji revisited: cytogenetics of the original Burkitt's lymphoma cell line.
Leukemia 19:159-161(2005)

PubMed=18357372; DOI=10.3892/or.19.4.889
Pop I., Pop L., Vitetta E.S., Ghetie M.-A.
Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein.
Oncol. Rep. 19:889-895(2008)

PubMed=19358282; DOI=10.1002/ijc.24351
Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M., Mori F., Ding J., Komatsu H., Iida S., Ueda R.
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Int. J. Cancer 125:212-221(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20454443; DOI=10.1155/2010/904767
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767-904767(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22885699; DOI=10.1038/nature11378
Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W., Zhang M., Wright G., Shaffer A.L., Hodson D.J., Buras E., Liu X., Powell J., Yang Y., Xu W., Zhao H., Kohlhammer H., Rosenwald A., Kluin P., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W., Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Nature 490:116-120(2012)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:E954893-E954893(2014)

PubMed=25355872; DOI=10.1128/JVI.02570-14
Cao S., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z., O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
J. Virol. 89:713-729(2015)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27566572; DOI=10.18632/oncotarget.11524
Quentmeier H., Pommerenke C., Ammerpohl O., Geffers R., Hauer V., MacLeod R.A.F., Nagel S., Romani J., Rosati E., Rosen A., Uphoff C.C., Zaborski M., Drexler H.G.
Subclones in B-lymphoma cell lines: isogenic models for the study of gene regulation.
Oncotarget 7:63456-63465(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29892436; DOI=10.1098/rsos.172472
Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M., Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S., Satoh M., Shimizu N., Kohara A.
Screening for 15 pathogenic viruses in human cell lines registered at the JCRB Cell Bank: characterization of in vitro human cells by viral infection.
R. Soc. Open Sci. 5:172472-172472(2018)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940-940(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

Cross-references
Cell line collections AddexBio; C0003009/4668
ATCC; CCL-86
ATCC; CRL-7936 - Discontinued
BCRC; 60116
BCRJ; 0211
CCTCC; GDC0191
CLS; 300359/p25072_RAJI
Coriell; GM04671
DSMZ; ACC-319
ECACC; 85011429
ICLC; HTL00002
IZSLER; BS TCL 54
JCRB; IFO50046
JCRB; JCRB9012
NCBI_Iran; C127
NIH-ARP; 9944-5
RCB; RCB1647
RCB; RCB3673
TKG; TKG 0371
Cell line databases/resources CLDB; cl4086
CLDB; cl4088
CLDB; cl4089
CLDB; cl4090
CLDB; cl4091
CLDB; cl4092
CLDB; cl4990
CCLE; RAJI_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
CCRID; 3111C0001CCC000046
CCRID; 3111C0002000000025
CCRID; 3131C0001000700044
CCRID; 3142C0001000001718
Cell_Model_Passport; SIDM00844
CGH-DB; 9204-4
Cosmic-CLP; 909262
DepMap; ACH-000654
GDSC; 909262
IHW; IHW04994
IGRhCellID; Raji
IPD-IMGT/HLA; 11295
LINCS_LDP; LCL-2025
Lonza; 726
TOKU-E; 2967
Ontologies BTO; BTO:0001154
CLO; CLO_0008734
CLO; CLO_0019014
CLO; CLO_0050995
EFO; EFO_0002324
MCCL; MCC:0000409
Biological sample resources BioSample; SAMN01821589
BioSample; SAMN01821656
BioSample; SAMN01821715
BioSample; SAMN01821738
BioSample; SAMN03473128
BioSample; SAMN10987653
ENCODE; ENCBS260AAA
Chemistry resources ChEMBL-Cells; CHEMBL3307663
ChEMBL-Targets; CHEMBL614628
PharmacoDB; Raji_1282_2019
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM33154
GEO; GSM99387
GEO; GSM887523
GEO; GSM888605
GEO; GSM1374840
GEO; GSM1374841
GEO; GSM1374842
GEO; GSM1602232
GEO; GSM1602233
GEO; GSM1602234
GEO; GSM1602235
GEO; GSM1602236
GEO; GSM1602237
GEO; GSM1602238
GEO; GSM1602241
GEO; GSM1602242
GEO; GSM1602243
GEO; GSM1602244
GEO; GSM1670357
Other Wikidata; Q4215980
Polymorphism and mutation databases Cosmic; 687850
Cosmic; 850211
Cosmic; 850387
Cosmic; 851997
Cosmic; 909262
Cosmic; 919136
Cosmic; 929816
Cosmic; 931110
Cosmic; 932761
Cosmic; 991549
Cosmic; 998718
Cosmic; 1019313
Cosmic; 1037703
Cosmic; 1070707
Cosmic; 1071883
Cosmic; 1082517
Cosmic; 1107179
Cosmic; 1127266
Cosmic; 1176615
Cosmic; 1191688
Cosmic; 1483367
Cosmic; 1517664
Cosmic; 1818346
Cosmic; 2301566
Cosmic; 2361386
Cosmic; 2649241
IARC_TP53; 704
IARC_TP53; 21706
LiGeA; CCLE_651
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number31